INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely

But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn ...

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs ...
Yahoo Finance

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 ...

Anthropic reportedly acquires medical AI startup Coefficient Bio for $400M+

Anthropic PBC has reportedly acquired Coefficient Bio Inc., a provider of artificial intelligence software for medical ...
AFN

21st Bio on strains, scale, and the valley of death: Fixing precision fermentation’s weak links

Can tiny biological production factories ever give petrochemicals or animals a run for their money? 21st Bio weighs ...

Bio-based polymer offers a sustainable solution to 'forever chemical' cleanup

Researchers at the University of Bath have discovered a renewable, bio-based polymer membrane capable of efficiently ...
Mirage News

Refeyn Debuts MyMass for Streamlined Bio Sample Tests

Compact, all-in-one mass photometer helps researchers verify sample quality before proceeding to cryo-EM, native MS, BLI, SPR, and other costly ...

Zura Bio: Momentum Is Real, But TibuSHIELD Needs To Deliver

Zura Bio (ZURA) stock update: tibulizumab enters Phase 2 for HS/SSc, cash runway to 2028, and key differentiation risks.
Mena FN

Inmune Bio's Mindful Trial Featured At AD/PD 2026 Plenary As Successful Example Of How To Approach Clinical Trials Targeting Inflammation In Early Alzheimer's Disease

(MENAFN- GlobeNewsWire - Nasdaq) Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer's Drug Development ...